The Management of Advanced Stage Hepatocellular Carcinoma

Transcription

1 The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior Consultant Surgeon, Singapore General Hospital APASL Single Topic Conference on HCC 23 rd Nov 2013, Cebu

2 HCC is a difficult Cancer to Treat Patients with HCC usually suffer from 2 diseases simultaneously Liver cirrhosis (Chronic Hepatitis B or C) 80% have cirrhosis Liver function can be poor Cancer Synergistic impact on treatment and outcomes 2

3 What is Advanced Stage HCC? A Hepatologist s definition (1) AASLD 2010

4 What is Advanced Stage HCC? Another Hepatologist s definition (2) APASL 2010

5 What is Advanced Stage HCC? APASL 2010 AASLD 2010 No Staging in APASL Guidelines

6 What is Advanced Stage HCC? An Oncologist s definition

7 RHV Features of Advanced HCC (1) Vascular Invasion RPV Challenge: not synonymous with un-resectable 7

8 Features of Advanced HCC (2) Distant metastases No Challenge: un-resectable (especially if synchronous) 8

9 Un-resectable but not Advanced HCC by AASLD 9

10 Categories of Advanced HCC The current practice in the Asia-Pacific is that AASLD stage does not always dictate APASL practice recommendations Broad categories of Advanced HCC Metastatic disease Locally advanced disease with vascular invasion 10

11 Oncology Guidelines: HCC not amendable to resection, transplantation, RFA

12 The management of metastatic HCC Systemic therapy required if there is adequate liver function Metastatic HCC and Child-Pugh A (or early B) Sorafenib is the standard of care Enrolment in clinical trial Metastatic HCC and Child-Pugh late B or C Best supportive care 12

13 Management of metastatic HCC APASL 2010 AASLD 2010

14 The management of HCC with Vascular Invasion continues to evolve Generally poor prognosis Poor liver function supportive management Good liver function Surgical resection (some centers especially in Asia) Selective Internal Radiation Therapy with yttrium-90 Sorafenib External beam radiation TACE (a relative contraindication) 14

15 Outcomes of surgical resection for HCC with PVT Lau WY et al 2013 Oncology 15

16 APASL 2010 * 16

17 The management of HCC with vascular invasion continues to evolve Generally poor prognosis Poor liver function supportive management Good liver function Surgical resection (some centers especially in Asia) Selective Internal Radiation Therapy with yttrium-90 Sorafenib External beam radiation TACE (a relative contraindication) 17

18 Selective Internal Radiation Therapy SIR-Spheres: μm diameter High-energy beta rays MeV 64.2 hrs (2.67 days) half-life Penetration: average penetration 2.5mm maximum range 11.0mm Ideal for Brachy-therapy 18

19 Post-therapy Bremsstrahlung Courtesy : A Goh

20 90 Y microspheres in Patients with HCC and PVT

21 90 Y microspheres in Patients with HCC and PVT Data from 103 patients (not enrolled in clinical trials from Singapore General Hospital/National Cancer Center Singapore

22 The management of HCC with vascular invasion continues to evolve Generally poor prognosis Poor liver function supportive management Good liver function Surgical resection (some centers especially in Asia) Selective Internal Radiation Therapy with yttrium-90 Sorafenib External beam radiation TACE (a relative contraindication) 22

23 Sorafenib: proposed mechanism Tumor cell proliferation Paracrine stimulation Tumor angiogenesis PDGF-β VEGF KIT/Flt-3/ RET Raf Ras Apoptosis PDGFR-β Ras Raf VEGFR-2 MEK ERK EGF PDGF Apoptosis MEK ERK Nucleus VEGF Proliferation Nucleus Angiogenesis Survival Sorafenib Wilhelm SM et al. Cancer Res

24 Asia-Pacific Sorafenib Trial: Overall Survival with/without MVI and/or EHS Survival Distribution Function With MVI/EHS Without MVI/EHS Nexavar (n=118) Median: 5.6 months (95% CI: 4.8, 6.7) Placebo (n=61) Median: 4.1 months (95% CI: 3.4, 4.8) 0.75 Nexavar (n=32) Median: 14.3 months (95% CI: 10.8, NR) Placebo (n=15) Median: 8.0 months (95% CI: 3.3, NR) HR (S/P): % CI: 0.54, HR (S/P): % CI: 0.19, Months from Randomization Adapted from Khang, et al. Presented at AASLD 2008 Annual Meeting. Oct 31 - Nov 4; San Francisco, CA, USA.

25 The management of HCC with vascular invasion continues to evolve Generally poor prognosis Poor liver function supportive management Good liver function Surgical resection (some centers especially in Asia) Selective Internal Radiation Therapy with yttrium-90 Sorafenib External beam radiation TACE (a relative contraindication) 25

26 Pierce Chow FRCS, PhD Stereotactic Radiotherapy for PVT Xi et al PLOS One

27 27

28 The management of HCC with vascular invasion continues to evolve Generally poor prognosis Poor liver function supportive management Good liver function Surgical resection (some centers especially in Asia) Selective Internal Radiation Therapy with yttrium-90 Sorafenib External beam radiation TACE (a relative contraindication) 28

29 80 84 TACE median 7.1 months Conservative median 4.1 months A prospective comparative study of TACE in PVT in Asia Luo et al 2011 Ann Surg Onc 29

30 Segmental PVT Main PVT TACE median 10.2 months Conservative median 5.2 months TACE median 5.3 months Conservative median 3.4 months A prospective comparative study of TACE in PVT in Asia Luo et al 2011 Ann Surg Onc 30

31 Comparative Median Survival for Vascular Invasion Modality Surgery Yttrium-90 (SIRT) Sorafenib Stereotatic radiotherapy TACE IVC mo - Branch PVT mo mo 10.2 mo Main PVT mo 5.3 mo (MVI/EHD) 9.1 mo 5.3 mo Randomized Controlled Trials are required

32 How should clinicians decide on what the most appropriate treatment for a patient with advance HCC in the absence of phase III data 32

33 The choice of the best treatment depends on: the stage of the cancer the general health of the patient and the availability of cutting edge expertise and therapeutics The rapid evolution of new therapeutic modalities makes it increasingly challenging to deliver optimal care with the patient being managed sequentially by individual specialists 33

34 Multi-Disciplinary Tumor Board delivered treatment Oncologic Radiologist Pathologist Medical Oncologist Surgical Oncologist Radiation Oncologist Liver Surgeon Nuclear Medicine 34

35 Multi-Disciplinary Tumor Board delivered treatment Pathologist Oncologic Radiologist Radiation Oncologist Medical Oncologist Surgical Oncologist Liver Surgeon Nuclear Medicine 35

36 Thank You! 36